Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merrimack Files S-1, But Life-Science IPO Market Far From Ironclad

This article was originally published in The Pink Sheet Daily

Executive Summary

The cancer drug maker aims to raise as much as $172.5 million and bring liquidity to investors who have poured in more than $250 million.
Advertisement

Related Content

Aveo Signs J&J As Partner In Early-Stage RON Antibody Deal
Astellas Pays $125MM Up-Front To Share Rights To AVEO's Tivozanib
Astellas Pays $125MM Up-Front To Share Rights To AVEO's Tivozanib
Sanofi Broadens Portfolio By Licensing A Monoclonal Antibody From Merrimack

Topics

Advertisement
UsernamePublicRestriction

Register

PS072493

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel